Soligenix, Inc announced its lead investigators for the cutaneous T-cell lymphoma (CTCL) and psoriasis programs are presenting findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the… read more.
“We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with… read more.
Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World… read more.
Kyowa Kirin Co., Ltd announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe… read more.
Pfizer Inc. will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February… read more.
Sobi will unveil new data at the annual European Association for Haemophilia and Allied Disorders (EAHAD 2025) congress in Milan from the 4th – 7th February, 2025. Outcomes… read more.
Abivax SA, a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational,… read more.
United Therapeutics Corporation a public benefit corporation, announced that five posters across its commercial and development portfolio in pulmonary hypertension (PH) will be presented at the Pulmonary Vascular… read more.
Agenus Inc. a leader in immuno-oncology, announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of… read more.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced presentations at the 63rd Annual Meeting of… read more.
Bayer announced that new analyses from the Phase III FINEARTS-HF trial evaluating finerenone (Kerendia) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of… read more.
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
